Company profile
MGB Biopharma Limited is a UK company with status active founded in 2009 based in Scotland.
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
SH01 | Transaction MzQ0NDczOTI5NGFkaXF6a2N4
Published 25 Nov 2024 09:33
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Feb 2018 to 31 Mar 2020
MGB Biophamra propose conducting a Phase IIa study to confirm the safety, tolerability and efficacy of MGB-BP-3 in patients with Clostridium difficile-associated diarrhoea (CDAD). The US CDC has designated C. difficile as an urgent threat, as it affects almost half a million people annually in the US alone, with a high annual mortality rate of around 30,0...
1 Aug 2014 to 31 Jan 2016
MGB Biopharma is developing a new class of antibiotic originally discovered in the UK by researchers at the University of Strathclyde. The drug,MGB-BP-3, has a novel mechanism of action which means that resistant bacteria will not be a feature as is the case with existing antibiotics. The first indication to be developed is the treatment of Clostridium di...
1 Apr 2012 to 31 Mar 2013
MGB's preclinical candidate drug MGB BP3 is a potent anti-infective compound with high potency against Gram +ve bacteria, including life threatening highly resistant strains such as MRSA. The compound shows unusual physicochemical characteristics which make solubilisation very challenging As a result, MGB Biopharma has been forced to adopt an oral formula...
